NCT00177021

Aldara for the Treatment of Extensive Alopecia Areata

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (planned)
• Sponsor: Hordinsky, Maria K., MD · Individual
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

We propose to examine the efficacy and tolerability of Aldara Cream 5% for the treatment of extensive alopecia areata. Aldara is a immune-response modifier. The drug induces the production of cytokines which are small, hormone-like proteins involved in cellular communication during immune responses. We hypothesize that this drug will effect the inflammatory cells present around hair follicles in patients with alopecia areata.

Detailed description

Ten patients with extensive scalp alopecia areata (\>95% hair loss)of less than 2 years duration will be invited to participate in this study. For six months each person will be asked to apply Aldara Cream 5% daily to the right half of the scalp. No drug will be applied to the left side. Skin biopsies will be taken of the right scalp before and at the completion of the therapy.

Conditions

• Alopecia Areata

Interventions

Type	Name	Description
DRUG	Aldara Cream 5%

Timeline

• Start date: 2000-10-01
• Completion: 2002-08-01
• First posted: 2005-09-15
• Last updated: 2006-11-13

Locations

1 site across 1 country: United States